NDAINJECTIONINJECTABLE
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CARDIZEM (diltiazem hydrochloride) by Ichnos Glenmark Innovation is clinical pharmacology the therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for hypertension, chronic stable angina, angina due to coronary artery spasm. First approved in 1991.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM (diltiazem hydrochloride) is a non-dihydropyridine calcium channel blocker administered via injection for treatment of hypertension, chronic stable angina, and vasospastic angina. It works by inhibiting calcium ion influx into cardiac and vascular smooth muscle, reducing peripheral vascular resistance and myocardial oxygen demand while increasing coronary blood flow.
$0.224MPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($224K in 2023), CARDIZEM is a legacy injectable product with limited growth prospects and likely smaller commercial infrastructure compared to oral antihypertensives.
Mechanism of Action
CLINICAL PHARMACOLOGY The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Mechanisms of Action Hypertension: Diltiazem produces its antihypertensive effect…
Worked on CARDIZEM at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.